Literature DB >> 17255834

Risk factors for small bowel bacterial overgrowth in cystic fibrosis.

Jacqueline L Fridge1, Carol Conrad, Lauren Gerson, Ricardo O Castillo, Kenneth Cox.   

Abstract

OBJECTIVES: The purpose of this study was to determine the prevalence of small bowel bacterial overgrowth in patients with pancreatic-insufficient cystic fibrosis (CF) compared with age-matched controls and to identify potential risk factors for small bowel bacterial overgrowth. PATIENTS AND METHODS: Fifty patients, 25 pancreatic-insufficient CF study patients (mean age, 17 y) and 25 gastrointestinal clinic control patients (mean age, 15 y), completed a glucose-hydrogen breath test after an overnight fast. Study patients completed a quality-of-life questionnaire modified from the Cystic Fibrosis Questionnaire. The medical history of each patient was compared with breath test results. A positive breath test was defined as a fasting hydrogen > or =15 ppm or a rise of > or =10 ppm hydrogen over baseline during the test.
RESULTS: The prevalence of positive breath tests was higher in the CF study group (56%) than in the control group (20%) (P = 0.02). The mean fasting hydrogen levels of patients in the study and control groups were 22 and 5 ppm (P = 0.0001). The mean questionnaire scores were not significantly different between breath test-positive and -negative study patients. The use of azithromycin was associated with an increased risk of a positive breath test. Use of laxatives and inhaled ipratropium was associated with a decreased risk of a positive breath test.
CONCLUSIONS: Patients with CF were more likely to have elevated fasting hydrogen levels compared with controls. This suggests a high prevalence of small bowel bacterial overgrowth in CF patients. Medications commonly used by CF patients may influence intestinal health.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17255834     DOI: 10.1097/MPG.0b013e31802c0ceb

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  29 in total

Review 1.  Cystic fibrosis: an inherited disease affecting mucin-producing organs.

Authors:  Camille Ehre; Caroline Ridley; David J Thornton
Journal:  Int J Biochem Cell Biol       Date:  2014-03-28       Impact factor: 5.085

2.  Cystic fibrosis mouse model-dependent intestinal structure and gut microbiome.

Authors:  Mark Bazett; Lisa Honeyman; Anguel N Stefanov; Christopher E Pope; Lucas R Hoffman; Christina K Haston
Journal:  Mamm Genome       Date:  2015-02-27       Impact factor: 2.957

Review 3.  Beyond pancreatic insufficiency and liver disease in cystic fibrosis.

Authors:  Stephanie Demeyer; Kris De Boeck; Peter Witters; Katrien Cosaert
Journal:  Eur J Pediatr       Date:  2016-04-07       Impact factor: 3.183

4.  Why bother to take vitamins?

Authors:  Alison Morton
Journal:  J R Soc Med       Date:  2011-07       Impact factor: 5.344

5.  The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin.

Authors:  Manuele Furnari; Alessandra De Alessandri; Federico Cresta; Maria Haupt; Marta Bassi; Angela Calvi; Riccardo Haupt; Giorgia Bodini; Iftikhar Ahmed; Francesca Bagnasco; Edoardo Giovanni Giannini; Rosaria Casciaro
Journal:  J Gastroenterol       Date:  2018-09-19       Impact factor: 7.527

6.  Gastrointestinal pathology in juvenile and adult CFTR-knockout ferrets.

Authors:  Xingshen Sun; Alicia K Olivier; Yaling Yi; Christopher E Pope; Hillary S Hayden; Bo Liang; Hongshu Sui; Weihong Zhou; Kyle R Hager; Yulong Zhang; Xiaoming Liu; Ziying Yan; John T Fisher; Nicholas W Keiser; Yi Song; Scott R Tyler; J Adam Goeken; Joann M Kinyon; Matthew C Radey; Danielle Fligg; Xiaoyan Wang; Weiliang Xie; Thomas J Lynch; Paul M Kaminsky; Mitchell J Brittnacher; Samuel I Miller; Kalpaj Parekh; David K Meyerholz; Lucas R Hoffman; Timothy Frana; Zoe A Stewart; John F Engelhardt
Journal:  Am J Pathol       Date:  2014-03-15       Impact factor: 4.307

7.  Lubiprostone decreases mouse colonic inner mucus layer thickness and alters intestinal microbiota.

Authors:  Mark W Musch; Yunwei Wang; Erika C Claud; Eugene B Chang
Journal:  Dig Dis Sci       Date:  2013-01-18       Impact factor: 3.199

8.  Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype.

Authors:  Robert C De Lisle; Racquel Mueller; Eileen Roach
Journal:  BMC Gastroenterol       Date:  2010-09-15       Impact factor: 3.067

9.  Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor.

Authors:  Drucy Borowitz; Barry Lubarsky; Michael Wilschanski; Anne Munck; Daniel Gelfond; Frank Bodewes; Sarah Jane Schwarzenberg
Journal:  Dig Dis Sci       Date:  2015-08-07       Impact factor: 3.199

Review 10.  The gastrointestinal mucus system in health and disease.

Authors:  Malin E V Johansson; Henrik Sjövall; Gunnar C Hansson
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-12       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.